These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37317870)

  • 21. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.
    Thebault S; Lee H; Bose G; Tessier D; Abdoli M; Bowman M; Berard J; Walker L; Rush CA; MacLean H; Booth RA; Narayanan S; Arnold DL; Tabard-Cossa V; Atkins HL; Bar-Or A; Freedman MS
    Ann Clin Transl Neurol; 2020 May; 7(5):767-775. PubMed ID: 32304358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
    Theodorsdottir A; Larsen PV; Nielsen HH; Illes Z; Ravnborg MH
    Acta Neurol Scand; 2022 Mar; 145(3):332-347. PubMed ID: 34799851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G
    Mult Scler; 2022 Apr; 28(4):561-572. PubMed ID: 34304609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
    Williams T; Tur C; Eshaghi A; Doshi A; Chan D; Binks S; Wellington H; Heslegrave A; Zetterberg H; Chataway J
    Mult Scler; 2022 Oct; 28(12):1913-1926. PubMed ID: 35946107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
    Hernandez L; O'Donnell M; Postma M;
    Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G
    Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers.
    Kim KW; Lee EJ; Kim SY; Jung HJ; Kim HJ; Kim S; Kim H; Seo D; So J; Kim J; Kim H; Kim KK; Lim YM
    Sci Rep; 2023 Mar; 13(1):3988. PubMed ID: 36894677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G
    Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
    Petzold A; Eikelenboom MJ; Gveric D; Keir G; Chapman M; Lazeron RH; Cuzner ML; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    Brain; 2002 Jul; 125(Pt 7):1462-73. PubMed ID: 12076997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
    Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enrichment strategy for clinical trials in SPMS.
    Koch MW; Metz L; Cutter G
    Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.